Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) CAO Sells $108,456.05 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CAO Kristen Ambrose sold 223 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $108,456.05. Following the transaction, the chief accounting officer owned 6,981 shares in the company, valued at $3,395,209.35. The trade was a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Kristen Ambrose also recently made the following trade(s):

• On Wednesday, February 11th, Kristen Ambrose sold 1,376 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $460.43, for a total transaction of $633,551.68.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $496.83 on Friday. The firm has a 50 day simple moving average of $466.55 and a 200 day simple moving average of $432.29. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68. The firm has a market cap of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.98 earnings per share. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Royal Bank Of Canada cut their target price on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research report on Friday, February 13th. UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Morgan Stanley restated an “overweight” rating and issued a $570.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Barclays lifted their target price on shares of Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a report on Tuesday, February 17th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $542.00.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several hedge funds have recently bought and sold shares of VRTX. Brighton Jones LLC increased its position in shares of Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. AlphaQuest LLC grew its stake in Vertex Pharmaceuticals by 18.8% in the second quarter. AlphaQuest LLC now owns 455 shares of the pharmaceutical company’s stock valued at $203,000 after acquiring an additional 72 shares during the period. Advisory Alpha LLC grew its stake in Vertex Pharmaceuticals by 12.4% in the second quarter. Advisory Alpha LLC now owns 1,701 shares of the pharmaceutical company’s stock valued at $757,000 after acquiring an additional 187 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $243,000. Finally, Jennison Associates LLC raised its position in shares of Vertex Pharmaceuticals by 21.5% during the second quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock worth $2,738,650,000 after purchasing an additional 1,089,063 shares during the period. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.